Safety, Tolerability, and Immunogenicity of NeomiVac, a Next-Generation mRNA–Lipid Nanoparticle Vaccine Comprising a Novel Ionisable Lipid: A First-In-Human, Phase 1, Dose-Escalation Trial

Angelica Vaccaro, Jordon Rolt, Nicole Frumento, Ola Diebold, Stephen M. Laidlaw, Susanna Shier, A. C. Brown, Clement Twumasi, Victoria Walker, Heinrich Haas, James Smith, Manuela Zonca, Hannah Emami, Eran Eilat, Fatemeh Moussavi-Pourgharbi, Alison M. Lawrie, Caroline Maxwell, Mwila Kasanyinga, Nicola M. Greenwood, Srinivas Ramishetti, Denis Bešić, Surender Vashist, Jan Egberts, César López‐Camacho, Adrian V. S. Hill, Dan Peer, Miles W. Carroll, E Barnes, Paola Cicconi